• Monday Feb. 6th at 12:00pm: BC Cancer Research Seminar Series presents “Understanding the Neuroendocrine Phenotype in Prostate Cancer” by Dr. Himisha Beltran
While most castration-resistant prostate cancers remain dependent on androgen receptor (AR) signaling, transformation to an AR-indifferent neuroendocrine phenotype can occur in later stages of disease progression. Dr. Beltran will present her research focused on the integration of clinical, pathologic, and molecular data of patients and discuss how she has used these data to understand mechanisms of treatment resistance and the biologic pathways driving progression of prostate adenocarcinoma to small cell/neuroendocrine prostate cancer.
February 06, 2017
from 12:00 PM to 01:00 PM
|Where||Gordon & Leslie Diamond Family Theatre - BC Cancer Agency Research Centre (675 W.10th Ave.)|
|Contact Name||Host: Dr. Kim Chi|
|Add event to calendar||
Himisha Beltran, MD
Assistant Professor of Medicine
Division of Medical Oncology
Weill Cornell Medicine
New York, NY
Himisha Beltran is a medical oncologist and physician scientist with a research focus in understanding mechanisms of treatment resistance in advanced prostate cancer. She has identified new therapeutic targets and biomarkers for neuroendocrine prostate cancer, an androgen independent subtype of castration resistant prostate cancer. As Director of Clinical Activities and Translational Research within the Englander Institute for Precision Medicine at Cornell, she continues to use genomic data to understand clonal evolution in cancer, develop novel biomarker and assays, and bring functionally validated drug targets into clinical application.